Segment information (Tables)
 12 Months Ended
Dec. 31, 2013
Segment information [Abstract]  
Segment information
The Biodefense division is directed to government-sponsored development and supply of countermeasures against potential agents of bioterror or biowarfare and targets the infectious disease anthrax. Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax® (Anthrax Vaccine Adsorbed), to the U.S. government. The Biosciences division is directed to commercial opportunities and primarily targets oncology indications, and consists of two business units, therapeutics and vaccines. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Biosciences. The assets in this segment consist primarily of cash.

 
 
Reportable Segments
 
(in thousands)
 
Biodefense
  
Biosciences
  
All Other
  
Total
 
Year Ended December 31, 2013
 
  
  
  
 
External revenue
 
$
311,564
  
$
1,181
  
$
-
  
$
312,745
 
Intersegment revenue (expense)
  
-
   
-
   
-
   
-
 
Research and development
  
62,663
   
50,652
   
6,618
   
119,933
 
Interest income
  
-
   
-
   
139
   
139
 
Interest expense
  
-
   
-
   
-
   
-
 
Depreciation and amortization
  
17,534
   
1,238
   
186
   
18,958
 
Net income (loss)
  
87,289
   
(50,925
)
  
(5,229
)
  
31,135
 
Intangible assets
  
30,148
   
-
   
-
   
30,148
 
In-process research and development assets
  
-
   
41,800
   
-
   
41,800
 
Goodwill
  
8,452
   
5,502
       
13,954
 
Total assets
  
331,827
   
98,510
   
196,293
   
626,630
 
Expenditures for long-lived assets
  
30,700
   
1,343
   
9,978
   
42,021
 
Year Ended December 31, 2012
                
External revenue
 
$
276,469
  
$
5,419
  
$
-
  
$
281,888
 
Intersegment revenue (expense)
  
-
   
-
   
-
   
-
 
Research and development
  
68,579
   
44,588
   
7,059
   
120,226
 
Interest income
  
-
   
-
   
134
   
134
 
Interest expense
  
-
   
-
   
(6
)
  
(6
)
Depreciation and amortization
  
8,951
   
2,147
   
99
   
11,197
 
Net income (loss)
  
94,865
   
(63,928
)
  
(7,413
)
  
23,524
 
In-process research and development assets
  
-
   
41,800
   
-
   
41,800
 
Goodwill
  
-
   
5,502
   
-
   
5,502
 
Total assets
  
354,010
   
56,148
   
154,072
   
564,230
 
Expenditures for long-lived assets
  
52,957
   
810
   
78
   
53,845
 
Year Ended December 31, 2011
                
External revenue
 
$
251,037
  
$
22,347
  
$
-
  
$
273,384
 
Intersegment revenue (expense)
  
-
   
-
   
-
   
-
 
Research and development
  
57,833
   
61,566
   
5,433
   
124,832
 
Interest income
  
-
   
-
   
105
   
105
 
Interest expense
  
-
   
-
   
-
   
-
 
Depreciation and amortization
  
6,213
   
3,070
   
72
   
9,355
 
Net income (loss)
  
86,836
   
(56,438
)
  
(7,379
)
  
23,019
 
In-process research and development assets
  
-
   
51,400
   
-
   
51,400
 
Goodwill
  
-
   
5,502
   
-
   
5,502
 
Total assets
  
290,302
   
92,321
   
164,241
   
546,864
 
Expenditures for long-lived assets
  
52,326
   
1,608
   
92
   
54,026